RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  2009-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-09-0679PMID 19706763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

  2008cited by this paper
• Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

  2008cited by this paper
• Changing population characteristics, effect-measure modification, and cancer risk factor identification

  2007cited by this paper
• Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

  2007cited by this paper
• Clinical experience of MEK inhibitors in cancer therapy.

  2007cited by this paper
• AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

  2007cited by this paper
• From Molecular Biology to Targeted Therapies for Hepatocellular Carcinoma: The Future Is Now

  2007cited by this paper
• Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy

  2007cited by this paper
• Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

  2007cited by this paper
• Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

  2007cited by this paper
• The MEK/ERK cascade: from signaling specificity to diverse functions.

  2007cited by this paper
• Regulation of MAPKs by growth factors and receptor tyrosine kinases.

  2007cited by this paper
• Recent advances of MEK inhibitors and their clinical progress.

  2007cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.

  2005cited by this paper
• Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.

  2005cited by this paper
• Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004influential reference
• Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.

  2004cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

  2003cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• The EGF receptor: structure, regulation and potential role in malignancy.

  1985cited by this paper

• Allosteric PROTACs: Expanding the Horizon of Targeted Protein Degradation

  2026cites this paper
• Hydrogen Sulfide Expression May Affect Ovarian Cancer Progression and Drug Resistance

  2025cites this paper
• Phosphoproteomic and Acetylomic Characterization of Colorectal Cancer Cells Treated with Kinase Inhibitors.

  2025cites this paper
• System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells

  2025cites this paper
• Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma

  2025cites this paper
• RHOGTPase-Related Gene Signature Predicts Prognosis, Immunotherapy Response, and Chemotherapy Sensitivity in Colon Cancer

  2025cites this paper
• A Specialized and Enhanced Deep Generation Model for Active Molecular Design Targeting Kinases Guided by Affinity Prediction Models and Reinforcement Learning

  2025cites this paper
• MAPK signaling and angiopoietin-2 contribute to endothelial permeability in capillary malformations.

  2025cites this paper
• Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

  2025influential citation
• MAPK Signaling and Angiopoietin-2 Contribute to Endothelial Permeability in Capillary Malformations

  2025cites this paper
• Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer.

  2025cites this paper
• Structural Insights on the Role of Halogen Bonding in Protein MEK Kinase-Inhibitor Complexes.

  2024cites this paper
• An immune biomarker associated with EMT serves as a predictor for prognosis and drug response in bladder cancer

  2024cites this paper
• Photocatalytic O- to S-Rearrangement of Tertiary Cyclopropanols.

  2024cites this paper
• Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice

  2023cites this paper
• A clinically relevant selective ERK-pathway inhibitor reverses core deficits in a mouse model of autism

  2023cites this paper
• Navigating the ERK1/2 MAPK Cascade

  2023cites this paper
• Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor

  2023cites this paper
• Entanglement of MAPK pathways with gene expression and its omnipresence in the etiology for cancer and neurodegenerative disorders.

  2023cites this paper
• MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives.

  2023cites this paper
• Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma

  2023cites this paper
• Enhancement of Anticancer Effects by Combining 5-Fluorouracil with Refametinib in Human Oral Squamous Cell Carcinoma Cell Line

  2023cites this paper
• Identifying Potential Molecular Targets in Fungi Based on (Dis)Similarities in Binding Site Architecture with Proteins of the Human Pharmacolome

  2023cites this paper
• Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

  2022cites this paper
• A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer

  2022cites this paper
• Establishment of a novel method to assess MEK1/2 inhibition in PBMCs for clinical drug development

  2022influential citation
• Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges

  2022cites this paper
• MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer’s Disease

  2022cites this paper
• Regioselective Alkylpolyfluoroarylation of Styrenes by Copper-Catalyzed C(sp3)-H and C(sp2)-H Double Activation.

  2022cites this paper
• Advances in Immunosuppressive Agents Based on Signal Pathway

  2022cites this paper
• Computational targeting of allosteric site of MEK1 by quinoline‐based molecules

  2022influential citation
• How Do Modulators Affect the Orthosteric and Allosteric Binding Pockets?

  2022cites this paper
• Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling

  2022cites this paper
• Regulation of MAPK ERK1/2 Signaling by Phosphorylation: Implications in Physiological and Pathological Contexts

  2021cites this paper
• Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects.

  2021cites this paper
• Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation

  2021cites this paper
• RAF-MEK-ERK pathway in cancer evolution and treatment.

  2021cites this paper
• Identification of ACK1 inhibitors as anticancer agents by using computer-aided drug designing

  2021cites this paper
• Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

  2021cites this paper
• Comprehensive Analysis of Cyclin Family Gene Expression in Colon Cancer

  2021cites this paper
• Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.

  2021cites this paper
• Structured Bayesian variable selection for multiple correlated response variables and high-dimensional predictors

  2021cites this paper
• MEK inhibitors for the treatment of non-small cell lung cancer

  2021influential citation
• Use of Kinase Inhibitors to Correct (cid:1) F508-CFTR Function*

  2020cites this paper
• Copper-Catalyzed Direct C-H Alkylation of Polyfluoroarenes by Using Hydrocarbons as an Alkylating Source.

  2020cites this paper
• Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

  2020cites this paper
• Function, Structure and Topology of Protein Kinases

  2020cites this paper
• MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water

  2020cites this paper
• Development of Serum Calcium and Phosphorus as Safety Biomarkers for Drug‐Induced Systemic Mineralization

  2020cites this paper
• Novel N-(aryl/heteroaryl)-2-chlorobenzenesulfonamide derivatives: Synthesis and anticancer activity evaluation.

  2020cites this paper
• Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines*

  2020cites this paper
• Prediction of drug response in multilayer networks based on fusion of multiomics data.

  2020cites this paper
• The Inhibition of RasGRF2, But Not RasGRF1, Alters Cocaine Reward in Mice

  2019cites this paper
• Structured penalized regression for drug sensitivity prediction

  2019cites this paper
• Ocular Complications of Targeted Therapy

  2019cites this paper
• Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.

  2019cites this paper
• Clinical Ophthalmic Oncology

  2019cites this paper
• A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer

  2019cites this paper
• Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.

  2019cites this paper
• Design, synthesis and biological evaluation of MEK PROTACs.

  2019cites this paper
• Investigation of Crystal Structures in Structure-Based Virtual Screening for Protein Kinase Inhibitors

  2019cites this paper
• New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma

  2019cites this paper
• Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening.

  2019cites this paper
• MEK1/2 as a Therapeutic Target in Sickle Cell Disease

  2019cites this paper
• Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

  2018cites this paper
• The Role of ERK1/2 Activation in Sarpogrelate-Mediated Neuroprotection

  2018cites this paper
• Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells

  2018influential citation
• Retina The Role of ERK 1 / 2 Activation in Sarpogrelate-Mediated Neuroprotection

  2018cites this paper
• MEK inhibitors under development for treatment of non-small-cell lung cancer

  2018cites this paper
• FGF mediated MAPK and PI3K/Akt Signals make distinct contributions to pluripotency and the establishment of Neural Crest

  2018influential citation
• Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors.

  2018cites this paper
• A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

  2017cites this paper
• Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice.

  2017cites this paper
• Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

  2017cites this paper
• Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

  2017cites this paper
• Continuous Selective Hydrogenation of Refametinib Iodo-nitroaniline Key Intermediate DIM-NA over Raney Cobalt Catalyst at kg/day Scale with Online UV–Visible Conversion Control

  2017cites this paper
• PREX1 regulates ERK1/2 in breast cancer

  2017cites this paper
• Continuous Platinum‐Mediated Hydrogenation of Refametinib Iodo‐nitroaniline Key Intermediate DIM‐NA: The Combined Challenges of Selectivity and Catalyst Deactivation

  2017cites this paper
• Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1

  2017cites this paper
• Current Development Status of MEK Inhibitors

  2017cites this paper
• Inhibition of MAPK‐Erk pathway in vivo attenuates aortic valve disease processes in Emilin1‐deficient mouse model

  2017cites this paper
• Pathophysiology of aortic aneurysm: insights from human genetics and mouse models.

  2016cites this paper
• Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions

  2016cites this paper
• Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events

  2016cites this paper
• Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma

  2016cites this paper
• Ocular toxicities of MEK inhibitors and other targeted therapies.

  2016cites this paper
• Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

  2016cites this paper
• Allosteric modulators of MEK1: drug design and discovery

  2016cites this paper
• PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling*

  2016cites this paper
• Targeted therapy in low-grade serous ovarian carcinoma : characterization of MEK inhibitor response in novel patient-derived cell lines

  2016cites this paper
• Allosteric Regulation: Mechanism Study and Applications in Drug Discovery

  2016cites this paper
• MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease

  2016cites this paper
• MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

  2015cites this paper
• USAGE OF MEK INHIBITORS IN ONCOLOGy: RESULTS AND PERSPECTIVES

  2015cites this paper
• Novel drugs in clinical development for hepatocellular carcinoma

  2015cites this paper
• Drug Response and Resistance in Advanced NF-1-Associated Cancers

  2015cites this paper
• MEK 1 / 2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease

  2015cites this paper
• Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors

  2015cites this paper
• Impact of the mitogen‐activated protein kinase pathway on the subproteome of detergent‐resistant microdomains of colon carcinoma cells

  2015cites this paper
• Recent progress on MAP kinase pathway inhibitors.

  2015cites this paper